Overview

Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients

Status:
Terminated
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of bemiparin (low molecular weight heparin) for 3 months in the treatment of chronic foot ulcers in diabetic patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Spanish National Health System
Collaborators:
Carlos III Health Institute
Rovi Pharmaceuticals Laboratories
Treatments:
Bemiparin
Calcium heparin
Dalteparin
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin